Advice
Marketing Authorisaton withdrawn
In August 2023, the marketing authorisation for casirivimab and imdevimab (Ronapreve) was withdrawn.
Medicine details
- Medicine name:
- casirivimab and imdevimab (Ronapreve)
- SMC ID:
- SMC2553
- Indication:
Treatment of acute COVID-19 infection
- Pharmaceutical company
- Roche
- BNF chapter
- Infections
- Submission type
- Collaboration
- Status
- Withdrawn
- Date advice published
- 29 March 2023
Additional notes
In August 2023, the marketing authorisation for casirivimab and imdevimab (Ronapreve) was withdrawn.